Glucuronide conjugates of 4-aminobiphenyl and its N-hydroxy metabolites pH stability and synthesis by human and dog liver

Biochemical Pharmacology

Volumn 51, Issue 12, 1996, Pages 1679-1685

  Babu, Satram R ^a   Lakshmi, Vijaya M ^a   Huang, George Pen Wen ^a   Zenser, Terry V ^a,b   Davis, Bernard B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

4 aminobiphenyl; Acid lability; Glucuronidation; Liver slices; N glucuronides; N hydroxy 4 aminobiphenyl; N hydroxy N acetyl 4 aminobiphenyl

Indexed keywords

4 AMINOBIPHENYL N GLUCURONIDE; 4 BIPHENYLAMINE; BENZIDINE; N ACETYLBENZIDINE; N HYDROXY 4 BIPHENYLAMINE; N HYDROXY N ACETYL 4 AMINO BIPHENYL; RADIOISOTOPE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLADDER CANCER; CHEMICAL CARCINOGENESIS; CONJUGATION; CONTROLLED STUDY; DOG; GLUCURONIDATION; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; LIVER SLICE; METABOLITE; NONHUMAN; PH; PRIORITY JOURNAL;

AMINOBIPHENYL COMPOUNDS; ANIMALS; CARCINOGENS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; GLUCURONATES; HUMANS; HYDROGEN-ION CONCENTRATION; LIVER; MODELS, MOLECULAR;

EID: 0029936205     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00165-7     Document Type: Article

References (47)

1. Case RAM, Hosker MW, McDonald DB and Pearson JT, Tumors of the urinary bladder in workmen engaged in the manufacture and use of certain dyestuff intermediates in the British chemical industry. Br J Ind Med 11: 75-104, 1954.
2. Radomski JL, The primary aromatic amines: Their biological properties and structure-activity relationships. Annu Rev Pharmacol Toxicol 19: 129-157, 1979.
3. Haley TJ, Metabolism and pharmacokinetics of benzidine and its congeners in man and animals. Drug Metab Rev 13: 473-483, 1982.
4. Guerin MR and Buchanan MV, Environmental exposure to N-aryl compounds, in: Carcinogenic and Mutagenic Responses to Aromatic Amines and Nitroarenes (Eds. King CM, Romano LJ and Schuetzle D), pp. 37-45. Elsevier Science Publishing, New York, 1988.
5. Patriankos C and Hoffmann D, Chemical studies on tobacco smoke. J Anal Toxicol 3: 150-154, 1979.
6. Ross RK, Paganini-Hill A and Henderson BE, Epidemiology of bladder cancer. In: Diagnosis and Management of Genitourinary Cancer (Eds. Skinner DG and Leiskovsky G), pp. 23-31. W.B. Saunders, Philadelphia, PA, 1988.
7. Butler MA, Guengerich FP and Kadlubar FF, Metabolic oxidation of the carcinogens 4-aminobiphenyl and 4,4′-methylene-bis(2-chloroaniline) by human hepatic microsomes and by purified rat hepatic cytochrome P-450 monooxygenases. Cancer Res 49: 25-31, 1989.
8. PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86: 7696-7700, 1989.
9. Frederickson SM, Hatcher JF, Reznikoff CA and Swaminathan S, Acetyl transferase-mediated metabolic activation of N-hydroxy-4-aminobiphenyl by human uroepithelial cells. Carcinogenesis 13: 955-961, 1992.
10. Hein DW, Doll MA, Rustan TD, Gray K, Feng Y, Ferguson RJ and Grant DM, Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14: 1633-1638, 1993.
11. Minchin RF, Reeves PT, Teitel CH, McManus ME, Mojarrabi B, Ilett KF and Kadlubar FF, N- and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem Biophys Res Commun 185: 839-844, 1992.
12. Hein DW, Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 948: 37-66, 1988.
13. Grant DM, Blum M, Beer M and Meyer UA, Monomorphic and polymorphic human arylamine N-acetyltransferases: A comparison of liver isozymes and expressed products of two cloned genes. Mol Pharmacol 39: 184-191, 1991.
14. Blum M, Demierre A, Grant DM, Heim M and Meyer UA, Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci USA 88: 5237-5241, 1991.
15. Vineis P, Caporaso N, Tannenbaum SR, Skipper PL, Glogowski J, Bartsch H, Coda M, Talaska G and Kadlubar F, Acetylation phenotype, carcinogen-hemoglobin adducts, and cigarette smoking. Cancer Res 50: 3002-3004, 1990.
16. Vineis P, Bartsch H, Caporaso N, Harrington AM, Kadlubar FF, Landi MT, Malaveille C, Shields PG, Skipper P, Talaska G and Tannebaum SR, Genetically based N-acetyltransferase metabolic polymorphism and low-level environmental exposure to carcinogens. Nature 369: 154-156, 1994.
17. Yu MC, Skipper PL, Taghizadeh K, Tannenbaum SR, Chan KK, Henderson BE and Ross RK, Acetylator phenotype, aminobiphenyl-hemoglobin adduct levels, and bladder cancer risk in white, black, and Asian men in Los Angeles, California. J Natl Cancer Inst 86: 712-716, 1994.
18. Mommsen S, Barfod NM and Aagaard J, N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low risk population. Carcinogenesis 6: 199-201, 1985.
19. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE and Bryan GT, N-Acetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 29: 71-79, 1979.
20. Dutton GJ, Glucuronidation of Drugs and Other Compounds. CRC Press, Boca Raton, FL, 1980.
21. Mulder GJ, Coughtrie MWH and Burchell B, Glucuronidation. In: Conjugation Reactions in Drug Metabolism: An Integrated Approach (Ed. Mulder GJ, pp. 51-105. Taylor & Francis, New York, 1990.
22. Irshaid YM and Tephly TR, Isolation and purification of two human liver UDP-glucuronosyltransferases. Mol Pharmacol 31: 27-34, 1987.
23. Babu SR, Lakshmi VM, Hsu FF, Kane KE III, Zenser TV and Davis BB, N-Acetylbenzidine-N′-glucuronidation by human, dog, and rat liver. Carcinogenesis 14: 2605-2611, 1993.
24. Kadlubar FF, Miller JA and Miller EC, Hepatic microsomal N-glucuronidation and nucleic acid binding of N-hydroxy arylamines in relation to urinary bladder carcinogenesis. Cancer Res 37: 805-814, 1977.
25. Kadlubar FF, Dooley KL, Teitel CH, Roberts DW, Benson RW, Butler MA, Bailey JR, Young JF, Skipper PW and Tannenbaum SR, Frequency of urination and its effects on metabolism, pharmacokinetics, blood hemoglobin adduct formation, and liver and urinary bladder DNA adduct levels in beagle dogs given the carcinogen 4-aminobiphenyl. Cancer Res 51: 4371-4377, 1991.
26. Boyland E, Manson D and Orr SFD, The biochemistry of aromatic amines. 2. The conversion of arylamines into arylsulphamic acids and arylamine-N-glucosiduronic acids. Biochem J 65: 417-423, 1957.
27. Lee M-S and Wang CY, Synthesis of N-glucuronides of carcinogenic N-hydroxyarylamines. Carcinogenesis 5: 73-75, 1984.
28. Lakshmi VM, Mattammal MB, Spry LA, Kadlubar FF, Zenser TV and Davis BB, Metabolism and disposition of benzidine in the dog. Carcinogenesis 11: 139-144, 1990.
29. Westra JG, A rapid and simple synthesis of reactive metabolites of carcinogenic aromatic amines in high yield. Carcinogenesis 2: 355-357, 1981.
30. Babu SR, Lakshmi VM, Hsu FF, Zenser TV and Davis BB, Role of N-glucuronidation in benzidine-induced bladder cancer in dog. Carcinogenesis 13: 1235-1240, 1992.
31. Babu SR, Wongsurawat VJ, Zenser TV and Davis BB, Benzidine glucuronidation in dog liver. Carcinogenesis 14: 893-897, 1993.
32. Orzechowski A, Schrenk D, Schut HAJ and Block KW, Consequences of 3-methylcholanthrene-type induction for the metabolism of 4-aminobiphenyl in isolated rat hepatocytes. Carcinogenesis 15: 489-494, 1994.
33. Green LC, Skipper PL, Turesky RJ, Bryant MS and Tannenbaum SR, In vivo dosimetry of 4-aminobiphenyl in rats via a cysteine adduct in hemoglobin. Cancer Res 44: 4254-4259, 1984.
34. Bryant MS, Skipper PL, Tannenbaum SR and Maclure M, Hemoglobin adducts of 4-aminobiphenyl in smokers and non-smokers. Cancer Res 47: 602-608, 1987.
35. Bryant MS, Vineis P, Skipper PL and Tannenbaum SR, Hemoglobin adducts of aromatic amines. Associations with smoking status and type of tobacco. Proc Natl Acad Sci USA 85: 9788-9791, 1988.
36. Babu SR, Lakshmi VM, Owens IS, Zenser TV and Davis BB, Human liver glucuronidation of benzidine. Carcinogenesis 15: 2003-2007, 1994.
37. Babu SR, Lakshmi VM, Zenser TV and Davis BB, Glucuronidation of N-acetylbenzidine by human liver. Drug Metab Dispos 22: 922-927, 1994.
38. Wang CY, Zukowski K and Lee M, Glucuronidation of carcinogenic arylamine metabolites by rat liver microsomes. Biochem Pharmacol 34: 837-841, 1985.
39. Kaderlik KR, Mulder GJ, Turesky RJ, Lang NP, Teitel CH, Chiarelli MP and Kadlubar FF, Glucuronidation of N-hydroxy heterocyclic amines by human and rat liver microsomes. Carcinogenesis 15: 1695-1701, 1994.
40. Orzechowski A, Schrenk D, Bock-Hennig BS and Bock KW, Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyltransferases of the UGT1 gene complex. Carcinogenesis 15: 1549-1553, 1994.
41. Swaminathan S and Reznikoff CA, Metabolism and nucleic acid binding of N-hydroxy-4-acetylaminobiphenyl and N-acetoxy-4-acetylaminobiphenyl by cultured human uroepithelial cells. Cancer Res 52: 3286-3294, 1992.
42. Irving CC, Influence of the aryl group on the reaction of glucuronides of N-arylacethydroxamic acids with polynucleotides. Cancer Res 37: 524-528, 1977.
43. Poirer LA, Miller JA and Miller EC, The N- and ring-hydroxylation of 2-acetylaminofluorene and the failure to detect N-acetylation of 2-aminofluorene in the dog. Cancer Res 23: 790-800, 1963.
44. Lower GM Jr and Bryan GT, Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem Pharmacol 22: 1581-1588, 1973.
45. Wise RW, Zenser TV, Kadlubar FF and Davis BB, Metabolic activation of carcinogenic aromatic amines by dog bladder and kidney prostaglandin H synthase. Cancer Res 44: 1893-1897, 1984.
46. Kirlin WG, Trinidad A, Yerokun T, Ogolla F, Ferguson RJ, Andrews AF, Brady PK and Hein DW, Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol. Cancer Res. 49: 2448-2454, 1989.
47. Frederickson SM, Messing EM, Reznikoff CA and Swaminathan S, Relationship between in vivo acetylator phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Cancer Epidemiol Biomarkers Prev 3: 25-32, 1994.